Reklāma
Burning Rock Says FDA Grants Breakthrough Device Designation For OverC Multi-Cancer Blood Test
(RTTNews) - Burning Rock (BNR), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, announced Tuesday that its OverC Multi-Cancer Detection Blood Test (MCDBT) has been granted Breakthrough Device Designation by the US Food and Drug Administration (FDA), which is the third of its kind globally.
Under the FDA's Breakthrough Devices Program, the Breakthrough Device Designation is granted to certain medical devices that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions such as cancer.
OverC MCDBT is intended for early detection of multiple cancer types (esophageal, liver, lung, ovarian, and pancreatic cancers) in adults of either sex, aged 50-75 years old, at average risk for cancer.
Burning Rock received CE mark for its OverC MCDBT manufactured in both the US and China facilities. The FDA Breakthrough Device Designation granted for it would pave the way for a clearer registration path through confirmative performance validation and utility establishment.
U.S. Consumer Prices Inch Up In Line With Estimates In April
Wall Street Likely To Open On Negative Note
Bay Street Likely To Open On Mixed Note
FTSE 100 Rises 0.7%
CAC 40 Modestly Higher In Cautious Trade
DAX Up 0.8% On Selective Buying As Markets Await Clarity On Tariffs
Sensex, Nifty End Modestly Lower Due To Tariff Uncertainty
